Lee E W
Res Commun Chem Pathol Pharmacol. 1977 Dec;18(4):753-64.
The erythropoietic toxicity of cytarabine was reduced when mice were maintained in the anesthetized state by pentobarbital starting 1 hr before and lasting 1 hr after a series of doses of cytarabine given over a 4 hr period. Erythropoietic toxicity was determined by injecting 59Fe 48 or 72 hr after the last dose of cytarabine and measuring 59Fe in the circulating red blood cells 24 hr later (24 hr 59Fe uptake). Although pentobarbital alone had no effect on 24 hr 59Fe uptake either 48 or 72 hr after pentobarbital, the barbiturates reduced erythropoietic toxicity when cytarabine was given as 3 doses of 50 or 100 mg/kg every 2 hr and the effect was evaluated 48 hr after the last dose. Neither single nor multiple doses of cytarabine inhibited 59Fe uptake when 24 hr 59Fe uptake was measured 72 hr after cytarabine. However, if an initial dose of cytarabine (150 mg/kg) was given 12 hr prior to the multiple doses and 24 hr 59Fe up take was measured 72 hr after drug treatment, 59Fe uptake was inhibited, suggesting that the initial dose of cytarabine induced hemopoietic stem cells in the resting GO state to go into active cell cycle. Pentobarbital also protected against these latter effects of multiple doses of cytarabine. In contrast to the above, pentobarbital did not protect against the inhibitory effects of a single dose of cytarabine on 59Fe uptake. The above data show that pentobarbital protects against the cytotoxic effect of cytarabine on pronormoblasts and hemopoietic stem cells in cell cycle.
在一系列阿糖胞苷剂量于4小时内给予之前1小时开始并用戊巴比妥维持麻醉状态并在给药后持续1小时的情况下,小鼠阿糖胞苷的红细胞生成毒性降低。红细胞生成毒性通过在最后一剂阿糖胞苷后48或72小时注射59Fe并在24小时后测量循环红细胞中的59Fe(24小时59Fe摄取量)来确定。尽管单独使用戊巴比妥在戊巴比妥给药后48或72小时对24小时59Fe摄取量均无影响,但当阿糖胞苷以每2小时50或100mg/kg的3剂给药并在最后一剂后48小时评估效果时,巴比妥类药物降低了红细胞生成毒性。当在阿糖胞苷后72小时测量24小时59Fe摄取量时,单剂量或多剂量的阿糖胞苷均未抑制59Fe摄取。然而,如果在多剂量之前12小时给予初始剂量的阿糖胞苷(150mg/kg)并在药物治疗后72小时测量24小时59Fe摄取量,则59Fe摄取受到抑制,这表明阿糖胞苷的初始剂量诱导处于静止G0期的造血干细胞进入活跃细胞周期。戊巴比妥也能防止多剂量阿糖胞苷的这些后期效应。与上述情况相反,戊巴比妥不能防止单剂量阿糖胞苷对59Fe摄取的抑制作用。上述数据表明,戊巴比妥可防止阿糖胞苷对早幼红细胞和处于细胞周期中的造血干细胞的细胞毒性作用。